Akero Therapeutics, Inc. Accumulated Other Comprehensive Income
Akero Therapeutics, Inc. had Accumulated Other Comprehensive Income of $1.83 million as of 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2025-11-07
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.83M.
- 2025-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $988.00K.
- 2025-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.08M.
- 2024-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $948.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2025-09-30 | $1.83M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $988.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $1.08M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $948.00K 10-Q · filed 2025-11-07 |
| 2024-09-30 | $2.10M 10-Q · filed 2024-11-08 |
| 2024-06-30 | -$261.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | -$79.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $270.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | -$506.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$251.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $21.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $37.00K 10-K · filed 2024-02-29 |
| 2022-06-30 | -$3.00K 10-Q · filed 2022-08-05 |
| 2022-03-31 | -$30.00K 10-Q · filed 2022-05-06 |
| 2021-12-31 | -$27.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | -$17.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$9.00K 10-Q · filed 2021-08-13 |
| 2021-03-31 | -$2.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | -$3.00K 10-K · filed 2022-02-25 |
| 2020-09-30 | $16.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $90.00K 10-Q · filed 2020-08-12 |
| 2020-03-31 | $45.00K 10-Q · filed 2020-05-13 |
| 2019-12-31 | -$6.00K 10-K · filed 2021-03-16 |